TY - JOUR
T1 - Antibiotic perturbation of the murine gut microbiome enhances the adiposity, insulin resistance, and liver disease associated with high-fat diet
AU - Mahana, Douglas
AU - Trent, Chad M.
AU - Kurtz, Zachary D.
AU - Bokulich, Nicholas A.
AU - Battaglia, Thomas
AU - Chung, Jennifer
AU - Müller, Christian L.
AU - Li, Huilin
AU - Bonneau, Richard A.
AU - Blaser, Martin J.
N1 - Funding Information:
Supported in part by R01 DK090989 and 5T32AI007180-30, from the National Institutes of Health, the Simons Foundation, and by the Diane Belfer Program for Human Microbial Ecology, the C&D fund, and the Ziff Family Fund. 16S sequencing was performed at the NYU Genome Technology Center, a shared resource partially supported by the Cancer Center Support Grant, P30CA016087, at the Laura and Isaac Perlmutter Cancer Center.
Publisher Copyright:
© 2016 Mahana et al.
PY - 2016/4/27
Y1 - 2016/4/27
N2 - Background: Obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD) are serious health concerns, especially in Western populations. Antibiotic exposure and high-fat diet (HFD) are important and modifiable factors that may contribute to these diseases. Methods: To investigate the relationship of antibiotic exposure with microbiome perturbations in a murine model of growth promotion, C57BL/6 mice received lifelong sub-therapeutic antibiotic treatment (STAT), or not (control), and were fed HFD starting at 13weeks. To characterize microbiota changes caused by STAT, the V4 region of the 16S rRNA gene was examined from collected fecal samples and analyzed. Results: In this model, which included HFD, STAT mice developed increased weight and fat mass compared to controls. Although results in males and females were not identical, insulin resistance and NAFLD were more severe in the STAT mice. Fecal microbiota from STAT mice were distinct from controls. Compared with controls, STAT exposure led to early conserved diet-independent microbiota changes indicative of an immature microbial community. Key taxa were identified as STAT-specific and several were found to be predictive of disease. Inferred network models showed topological shifts concurrent with growth promotion and suggest the presence of keystone species. Conclusions: These studies form the basis for new models of type 2 diabetes and NAFLD that involve microbiome perturbation.
AB - Background: Obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD) are serious health concerns, especially in Western populations. Antibiotic exposure and high-fat diet (HFD) are important and modifiable factors that may contribute to these diseases. Methods: To investigate the relationship of antibiotic exposure with microbiome perturbations in a murine model of growth promotion, C57BL/6 mice received lifelong sub-therapeutic antibiotic treatment (STAT), or not (control), and were fed HFD starting at 13weeks. To characterize microbiota changes caused by STAT, the V4 region of the 16S rRNA gene was examined from collected fecal samples and analyzed. Results: In this model, which included HFD, STAT mice developed increased weight and fat mass compared to controls. Although results in males and females were not identical, insulin resistance and NAFLD were more severe in the STAT mice. Fecal microbiota from STAT mice were distinct from controls. Compared with controls, STAT exposure led to early conserved diet-independent microbiota changes indicative of an immature microbial community. Key taxa were identified as STAT-specific and several were found to be predictive of disease. Inferred network models showed topological shifts concurrent with growth promotion and suggest the presence of keystone species. Conclusions: These studies form the basis for new models of type 2 diabetes and NAFLD that involve microbiome perturbation.
UR - http://www.scopus.com/inward/record.url?scp=84964240579&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964240579&partnerID=8YFLogxK
U2 - 10.1186/s13073-016-0297-9
DO - 10.1186/s13073-016-0297-9
M3 - Article
C2 - 27124954
AN - SCOPUS:84964240579
SN - 1756-994X
VL - 8
JO - Genome Medicine
JF - Genome Medicine
IS - 1
M1 - 48
ER -